Brind.

MediWound received FDA approval for its biologic NexoBrid and announced its corporate structure and market presence.

3 reports, 2 independent Updated Sep 15

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

MediWound received FDA approval for its biologic NexoBrid and announced its corporate structure and market presence.

Who's involved

What this event is mainly about

MediWound (Germany)FDA

Keep exploring

The entities involved

MediWound (Germany)
company in Rüsselsheim, Germany

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.Jun 7

Coverage

Newest first; wire copies grouped

Sep 15jpost.com
Aug 20GlobeNewswireMediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic ther
Aug 4GlobeNewswireMediWound to Report Second Quarter 2025 Financial Results MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern